Replay available

Knight Therapeutics Inc. (GUD) Q3 2025 Earnings Call

Knight Therapeutics Inc. (TSX: GUD) Q3 2025 earnings conference call, held 2025-11-06. Replay captured from the company's public earnings webcast.

Thu, November 6, 2025 at 8:30 AMendedReplay
Knight Therapeutics Inc. (GUD) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Richard Clark

Analyst, Bernstein Research

Jed Kelly

Analyst, Oppenheimer & Co.

Doug Anmuth

Analyst, JPMorgan

Matt Goldberg

President and CEO

Mike Noonan

Chief Financial Officer

Nived Khan

Analyst, B. Riley Securities

Ronald Josie

Analyst, Citigroup

Nafisa Gupta

Analyst, Bank of America Securities

Angela White

Vice President, Investor Relations

Replay transcript excerpt

Hey, and thank you for standing by. Welcome to the TripAdvisor third quarter 2025 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Angela White, Vice President of Investor Relations. Angela, please go ahead. Thank you so much, Felicia. Good morning, and welcome to TripAdvisor's third quarter 2025 financial results call. Joining me today are Matt Goldberg, President and CEO, and Mike Noonan, CFO. Earlier this morning, we filed and made available our earnings release. In that release, you'll find reconciliations of non-GAAP financial measures to the most comparable GAAP financial measure discussed on this call. Before we begin, I'd like to remind you that this call may contain estimates and other forward-looking statements that represent management's views as of today, November 6, 2025. TripAdvisor disclaims any obligation to update these statements to reflect future events or circumstances. Please refer to our earnings release as well as our filings with the SEC for information concerning factors that could cause actual results to differ materially from these forward-looking statements. With that, I'll turn the call over to Matt. Thanks, Angela, and good morning, everyone. In Q3, we delivered consolidated revenue growth of 4% to $553 million. and adjusted EBITDA of 123 million, or 22% of revenue. We were pleased with this ...

More from Knight Therapeutics, Inc.